Show Summary Details
Page of

Breast cancer at a nuclear power station 

Breast cancer at a nuclear power station
Breast cancer at a nuclear power station

Adrian Harnett

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 01 March 2021

Breast cancer in young women is more likely to be hereditary and associated with a breast cancer gene (BRCA1 & BRCA2). When hereditary cancer is unlikely or been excluded as far as possible, a carcinogenic factor, such as drugs or radiation, may rarely be implicated. It is important to investigate this in the history. There may be indicators or points in the case that alert the clinician to an unusual presentation or pathology. Essentially, management is likely to be the same as for a standard invasive breast cancer, which may of course include breast reconstruction. There may be an increased risk of toxicity from treatment, depending on the patient’s individual situation. Late effects may also be increased, particularly as there is a risk of carcinogenesis causing further malignancies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.